Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Development and Evaluation of a Parent-led Intervention Module for Early Autism Spectrum Disorder (PRIME-ASD) in Odisha, India: Protocol for a Multiphase Mixed-methods Study Including an Open-label Randomised Controlled Trial

29. september 2026 opdateret af: Dr. Debadatta Mohapatra, All India Institute of Medical Sciences, Bhubaneswar

Many families of young children with autism in India wait a long time for a diagnosis and specialist therapy, and receive little structured guidance on how to help their child at home. PRIME-ASD is a 12-week programme in which a trained therapist coaches parents or other main caregivers to use simple, play-based activities within everyday household and cultural routines to support their child's social interaction, communication, emotions, behaviour, sensory responses and thinking skills.

This study will test whether PRIME-ASD, added to usual care, reduces autism symptoms more than usual care alone. A total of 188 children aged 2-9 years with autism attending AIIMS Bhubaneswar, Odisha, India, will be randomly assigned in equal numbers to receive PRIME-ASD plus usual care or usual care alone. Autism symptoms will be measured with the Indian Scale for Assessment of Autism (ISAA) by assessors who do not know which group the child is in. The main comparison is at 12 weeks; the study will also look at behaviour, social maturity, whether any benefit lasts to 24 weeks, whether families can take part and find the programme acceptable, and safety. Some caregivers will be interviewed about their experience of delivering the programme at home.

Studieoversigt

Detaljeret beskrivelse

Background. Parent-mediated interventions improve parent-child interaction and show smaller but consistent benefits for child social communication. Existing Indian adaptations were developed in other linguistic and service contexts and have not been co-designed with Odia-speaking families or aligned with the District Early Intervention Centres (DEIC) through which Odisha delivers early developmental services.

Development. PRIME-ASD was developed in earlier phases of a multiphase mixed-methods study: a systematic review and meta-analysis of randomised trials of parent-mediated interventions (registered with PROSPERO); in-depth interviews and focus groups with caregivers, providers and administrators; and a modified Delphi process (8-12 experts; consensus ≥80%) with content validation (I-CVI ≥0.78; S-CVI/Ave ≥0.80), face validation with 6-8 parents and field testing with 3-5 parent-child dyads. This record covers only the randomised controlled trial.

Design. Two-arm, parallel-group, open-label, assessor-blinded, superiority randomised controlled trial with 1:1 allocation and an embedded qualitative study, reported according to SPIRIT 2013 and CONSORT. Allocation uses a computer-generated sequence of randomly permuted blocks of variable size [2, 4 and 6], prepared by an independent statistician and concealed in sequentially numbered, opaque, sealed envelopes opened after the baseline assessment.

Intervention. PRIME-ASD comprises 12 weekly individual coaching sessions of about [60] minutes (didactic coaching, demonstration, coached caregiver-child practice with feedback and home-goal setting), weekly telephone follow-up of about [15-20] minutes and daily home practice of about [20-30] minutes across six domains aligned with the ISAA. Sessions are delivered in person at AIIMS Bhubaneswar, with synchronous video sessions when travel is not possible. Fidelity is monitored with attendance logs, home-practice checklists, an interventionist fidelity checklist and supervisor rating of [20%] of audio-recorded sessions.

Comparator. Treatment as usual (TAU): routine outpatient psychiatric review, psychoeducation and counselling, medication where clinically indicated and referral to available therapy services. TAU is not restricted in either arm, and co-interventions are recorded at each assessment.

Sample size. Assuming a standardised mean difference of 0.45 in ISAA score, two-sided α = 0.05 and 80% power, 79 children per arm are required; allowing for 15% attrition by 24 weeks, 94 per arm (188 in total) will be recruited.

Analysis. Intention to treat. The 12-week ISAA total score will be compared with analysis of covariance adjusted for baseline score [and any stratification factors]. Secondary outcomes will be analysed with linear mixed-effects models (arm, time, arm-by-time and baseline score) and logistic regression for response, without adjustment for multiplicity. Missing data will be handled by multiple imputation by chained equations, with complete-case, per-protocol and tipping-point sensitivity analyses. No interim efficacy analysis is planned.

Embedded qualitative study. After the 12-week assessment, approximately [15-20] intervention-arm caregivers, sampled on adherence and ISAA change, and the interventionists will be interviewed; findings will be merged with trial results in joint displays.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

188

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

2 år til 15 år (Barn)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Child aged 2-9 years Diagnosis of autism spectrum disorder according to ICD-11 criteria, made by a psychiatrist after clinical evaluation and supported by the INCLEN Diagnostic Tool for ASD [or ISAA - TO CONFIRM] A primary caregiver (biological parent, legal guardian or family member responsible for most daily care) aged 18 years or older who is willing and able to attend coaching sessions, take part in telephone follow-up and practise activities at home for 12 weeks Access to a mobile telephone Written informed consent from the caregiver or legally authorised representative

Exclusion Criteria:

  • Severe or profound intellectual disability [threshold and instrument] Uncontrolled epilepsy or another medical condition that precludes participation Uncorrected severe visual or hearing impairment Caregiver with a severe mental illness or other condition that would prevent delivery of the module Current enrolment in another structured parent-training programme Plans to leave the catchment area within 6 months

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: PRIME-ASD plus treatment as usual - Experimental

Children and their primary caregivers receive the 12-week PRIME-ASD parent-led intervention in addition to treatment as usual.

Twelve weekly individual coaching sessions of about [60] minutes with a caregiver-child dyad, delivered by a [clinical psychologist / trained research therapist] in person at AIIMS Bhubaneswar or by synchronous video. Each session includes brief didactic coaching, live or video demonstration, coached caregiver-child practice with feedback and collaborative home-goal setting. Caregivers practise play-based routines at home for about [20-30] minutes daily across six domains (social relationship and reciprocity; emotional responsiveness; speech, language and communication; behaviour patterns; sensory aspects; cognitive component) and receive a weekly telephone follow-up of about [15-20] minutes. Materials include an Odia-language manual, parent handouts, daily activity checklists and demonstration videos.

Aktiv komparator: Behavioral: PRIME-ASD; Other: Treatment as usual

Children continue treatment as usual alone, without restriction.

Children continue treatment as usual alone, without restriction.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in autism symptom severity (ISAA total score) at 12 weeks
Tidsramme: Baseline and 12 weeks

Indian Scale for Assessment of Autism (ISAA) total score, rated by a masked clinician. 40 items scored 1-5; total 40-200; higher scores indicate greater severity (lower is better). Between-arm adjusted mean difference with 95% CI, analysis of covariance adjusted for baseline score.

Baseline and 12 weeks

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Maintenance of change in ISAA total score
Tidsramme: Baseline and 24 weeks

ISAA total score (40-200; higher scores indicate greater severity), masked clinician rating; adjusted mean difference from a linear mixed-effects model.

Baseline and 24 weeks
Change in ISAA domain scores
Tidsramme: Baseline, 12 weeks and 24 weeks

Scores on the six ISAA domains (social relationship and reciprocity; emotional responsiveness; speech, language and communication; behaviour patterns; sensory aspects; cognitive component); higher scores indicate greater severity

Baseline, 12 weeks and 24 weeks
Change in behavioural symptoms (Aberrant Behavior Checklist-Community)
Tidsramme: Baseline, 12 weeks and 24 weeks

Caregiver-rated ABC-C total and five subscale scores (irritability; social withdrawal; stereotypic behaviour; hyperactivity/non-compliance; inappropriate speech); 58 items; higher scores indicate more problem behaviour.

Baseline, 12 weeks and 24 weeks
Proportion of responders
Tidsramme: 12 weeks and 24 weeks

Percentage of children with an ISAA reduction of at least 0.5 SD of the baseline score and, separately, a VSMS gain of at least 0.3 SD; adjusted odds ratio with 95% CI.

12 weeks and 24 weeks
Feasibility of the intervention
Tidsramme: Enrolment to 24 weeks

Recruitment rate, retention, session attendance, home-practice adherence and intervention fidelity, reported as proportions with 95% CI or median (IQR).

Enrolment to 24 weeks
Acceptability of the intervention
Tidsramme: 12 weeks

Caregiver-rated Acceptability of Intervention Measure, Intervention Appropriateness Measure and Feasibility of Intervention Measure (each scored 1-5; higher scores indicate greater acceptability, appropriateness or feasibility).

12 weeks
Number of participants with adverse events and serious adverse events
Tidsramme: Baseline to 24 weeks

Adverse events and serious adverse events by arm, severity and relatedness, from caregiver report and clinician review.

Baseline to 24 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

15. januar 2027

Primær færdiggørelse (Anslået)

14. december 2027

Studieafslutning (Anslået)

15. december 2027

Datoer for studieregistrering

Først indsendt

29. september 2026

Først indsendt, der opfyldte QC-kriterier

29. september 2026

Først opslået (Faktiske)

5. oktober 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

5. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

29. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner